1: Inta I, Bettendorf M, Gass P. Conserved Hypothalamic c-Fos Activation Pattern Induced by the mGlu5 Receptor Antagonist MPEP during Peri-pubertal Development in Mice. Pharmacopsychiatry. 2016 Jul;49(4):142-5. doi: 10.1055/s-0042-105018. Epub 2016 Apr 21. PubMed PMID: 27101232.

2: Lee JY, Choe ES, Yang CH, Choi KH, Cheong JH, Jang CG, Seo JW, Yoon SS. The mGluR5 antagonist MPEP suppresses the expression and reinstatement, but not the acquisition, of the ethanol-conditioned place preference in mice. Pharmacol Biochem Behav. 2016 Jan;140:33-8. doi: 10.1016/j.pbb.2015.10.015. Epub 2015 Oct 30. PubMed PMID: 26521964.

3: Zolkowska D, Kondrat-Wrobel MW, Florek-Luszczki M, Luszczki JJ. Influence of MPEP (a selective mGluR5 antagonist) on the anticonvulsant action of novel antiepileptic drugs against maximal electroshock-induced seizures in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Feb 4;65:172-8. doi: 10.1016/j.pnpbp.2015.10.005. Epub 2015 Oct 21. PubMed PMID: 26478256.

4: Nagel J, Greco S, Parsons CG, Flik G, Tober C, Klein KU, Danysz W. Brain concentrations of mGluR5 negative allosteric modulator MTEP in relation to receptor occupancy--Comparison to MPEP. Pharmacol Rep. 2015 Jun;67(3):624-30. doi: 10.1016/j.pharep.2015.01.004. Epub 2015 Jan 22. PubMed PMID: 25933979.

5: Gregory KJ, Malosh C, Turlington M, Morrison R, Vinson P, Daniels JS, Jones C, Niswender CM, Conn PJ, Lindsley CW, Stauffer SR. Identification of a high affinity MPEP-site silent allosteric modulator (SAM) for the metabotropic glutamate subtype 5 receptor (mGlu(5)). 2013 Apr 15 [updated 2015 Feb 11]. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-. Available from http://www.ncbi.nlm.nih.gov/books/NBK280039/ PubMed PMID: 25834893.

6: Nowak G, Pomierny-Chamioło L, Siwek A, Niedzielska E, Pomierny B, Pałucha-Poniewiera A, Pilc A. Prolonged administration of antidepressant drugs leads to increased binding of [(3)H]MPEP to mGlu5 receptors. Neuropharmacology. 2014 Sep;84:46-51. doi: 10.1016/j.neuropharm.2014.04.016. Epub 2014 May 4. PubMed PMID: 24796254.

7: Gandhi RM, Kogan CS, Messier C. 2-Methyl-6-(phenylethynyl) pyridine (MPEP) reverses maze learning and PSD-95 deficits in Fmr1 knock-out mice. Front Cell Neurosci. 2014 Mar 6;8:70. doi: 10.3389/fncel.2014.00070. eCollection 2014. PubMed PMID: 24701200; PubMed Central PMCID: PMC3965849.

8: Kumar J, Hapidin H, Bee YT, Ismail Z. Effects of the mGluR5 antagonist MPEP on ethanol withdrawal induced anxiety-like syndrome in rats. Behav Brain Funct. 2013 Nov 26;9:43. doi: 10.1186/1744-9081-9-43. PubMed PMID: 24279870; PubMed Central PMCID: PMC4222772.

9: Rodriguez AL, Tarr JC, Zhou Y, Williams R, Gregory KJ, Bridges TM, Daniels JS, Niswender CM, Conn PJ, Lindsley CW, Stauffer SR. Identification of a glycine sulfonamide based non-MPEP site positive allosteric potentiator (PAM) of mGlu(5). 2012 Dec 17 [updated 2013 Mar 22]. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-. Available from http://www.ncbi.nlm.nih.gov/books/NBK154499/ PubMed PMID: 24027804.

10: Zhou Y, Chun A, Gogliotti RD, Dawson ES, Vinson PN, Niswender CM, Noetzel MJ, Rook JM, Bridges TM, Daniels JS, Jones C, Conn PJ, Lindsley CW, Stauffer SR. Pure Positive Allosteric Modulators (PAMs) of mGlu5 with Competitive MPEP-Site Interaction. 2011 Oct 31 [updated 2013 Mar 7]. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-. Available from http://www.ncbi.nlm.nih.gov/books/NBK143535/ PubMed PMID: 23762950.

11: Morin N, Morissette M, Grégoire L, Gomez-Mancilla B, Gasparini F, Di Paolo T. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys. Neuropharmacology. 2013 Oct;73:216-31. doi: 10.1016/j.neuropharm.2013.05.028. Epub 2013 Jun 10. PubMed PMID: 23756168.

12: Managò F, Lopez S, Oliverio A, Amalric M, Mele A, De Leonibus E. Interaction between the mGlu receptors 5 antagonist, MPEP, and amphetamine on memory and motor functions in mice. Psychopharmacology (Berl). 2013 Apr;226(3):541-50. doi: 10.1007/s00213-012-2925-4. Epub 2012 Nov 29. PubMed PMID: 23192313.

13: Rodriguez AL, Zhou Y, Williams R, Weaver CD, Vinson PN, Dawson ES, Steckler T, Lavreysen H, Mackie C, Bartolomé JM, Macdonald GJ, Daniels JS, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Stauffer SR. Discovery and SAR of a novel series of non-MPEP site mGlu₅ PAMs based on an aryl glycine sulfonamide scaffold. Bioorg Med Chem Lett. 2012 Dec 15;22(24):7388-92. doi: 10.1016/j.bmcl.2012.10.068. Epub 2012 Oct 23. PubMed PMID: 23142615; PubMed Central PMCID: PMC3539767.

14: Cavas M, Scesa G, Navarro JF. Effects of MPEP, a selective metabotropic glutamate mGlu5 ligand, on sleep and wakefulness in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jan 10;40:18-25. doi: 10.1016/j.pnpbp.2012.09.011. Epub 2012 Sep 27. PubMed PMID: 23022670.

15: Manka JT, Vinson PN, Gregory KJ, Zhou Y, Williams R, Gogi K, Days E, Jadhav S, Herman EJ, Lavreysen H, Mackie C, Bartolomé JM, Macdonald GJ, Steckler T, Daniels JS, Weaver CD, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Stauffer SR. Optimization of an ether series of mGlu5 positive allosteric modulators: molecular determinants of MPEP-site interaction crossover. Bioorg Med Chem Lett. 2012 Oct 15;22(20):6481-5. doi: 10.1016/j.bmcl.2012.08.043. Epub 2012 Aug 24. PubMed PMID: 22981332; PubMed Central PMCID: PMC3755010.

16: Morin N, Grégoire L, Morissette M, Desrayaud S, Gomez-Mancilla B, Gasparini F, Di Paolo T. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates. Neuropharmacology. 2013 Mar;66:355-64. doi: 10.1016/j.neuropharm.2012.07.036. Epub 2012 Jul 31. PubMed PMID: 22884464.

17: Salomons AR, Pinzon NE, Boleij H, Kirchhoff S, Arndt SS, Nordquist RE, Lindemann L, Jaeschke G, Spooren W, Ohl F. Differential effects of diazepam and MPEP on habituation and neuro-behavioural processes in inbred mice. Behav Brain Funct. 2012 Jun 11;8:30. doi: 10.1186/1744-9081-8-30. PubMed PMID: 22686184; PubMed Central PMCID: PMC3464737.

18: Inta D, Filipovic D, Lima-Ojeda JM, Dormann C, Pfeiffer N, Gasparini F, Gass P. The mGlu5 receptor antagonist MPEP activates specific stress-related brain regions and lacks neurotoxic effects of the NMDA receptor antagonist MK-801: significance for the use as anxiolytic/antidepressant drug. Neuropharmacology. 2012 Apr;62(5-6):2034-9. doi: 10.1016/j.neuropharm.2011.12.035. Epub 2012 Jan 12. PubMed PMID: 22261382.

19: D'Souza MS, Markou A. Metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP) microinfusions into the nucleus accumbens shell or ventral tegmental area attenuate the reinforcing effects of nicotine in rats. Neuropharmacology. 2011 Dec;61(8):1399-405. doi: 10.1016/j.neuropharm.2011.08.028. Epub 2011 Aug 31. PubMed PMID: 21896278; PubMed Central PMCID: PMC3189265.

20: Chau P, Söderpalm B, Ericson M. The mGluR5 antagonist MPEP elevates accumbal dopamine and glycine levels; interaction with strychnine-sensitive glycine receptors. Addict Biol. 2011 Oct;16(4):591-9. doi: 10.1111/j.1369-1600.2011.00343.x. Epub 2011 Jul 25. PubMed PMID: 21790901.